Transatlantic takeover of drugmaker

Rosemont Pharmaceuticals, a leading Leeds-based developer, manufacturer and distributor of liquid pharmaceuticals, has acquired Sabal Therapeutics and its subsidiaries.

The agreement, which includes subsidiaries Metacel Pharmaceuticals, Palmetto Pharmaceuticals, Athena Bioscience and Sarras Health, concerns a group of privately held prescription drug companies and liquid medicine distributors headquartered in Georgia, USA.

The purpose of this acquisition is to further expand Rosemont’s ability to serve patients with swallowing difficulties throughout the United States.

Previously, the company developed, registered and delivered drugs to the U.S. market through distribution partners.

The acquisition will give the company the ability to supply branded and generic drugs directly to the U.S. market.

In addition to the existing portfolio included in this transaction, Rosemont has a broad pipeline of innovative liquid medicines for the U.S. market and for U.S. patients.

Howard Taylor, CEO of Rosemont, said: “The acquisition of Sabal is a significant milestone for us as we commercialize our world-class medicines to help American patients with swallowing difficulties, building on our platform of high-quality development teams in both the UK and Greece.

“Our Vice President of the U.S. Market, John Denman, who leads Rosemont Inc.’s U.S. operations, will lead this effort, and all of us at Rosemont look forward to working with the Sabal team.”

Sabal President and CEO Jeff Bryant added, “The combination of Rosemont and Sabal allows us to significantly expand our vision across therapeutic areas with the ultimate goal of improving the lives of patients.

“We are pleased to join the Rosemont team to deliver even greater value to our suppliers and the people in their care.”